Skip to content

Studies on pharmacokinetics of Wuzhi capsule and interactions of tacrolimus and Wuzhi capsule

Studies on pharmacokinetics of Wuzhi capsule and interactions of tacrolimus and Wuzhi capsule

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-12002216
Enrollment
Unknown
Registered
2012-05-28
Start date
2010-05-22
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Transplantation

Interventions

Group A:WZC 6 capsule
Group B:TAC administrated orally
Group C:TAC +WZC 1 capsule
Group D:TAC +WZC 2 capsules
Group E:TAC +WZC 6 capsules

Sponsors

Shanghai Changzheng Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
22 Years to 24 Years

Inclusion criteria

Inclusion criteria: 1. voluntarily participate in clinical trials and provided informed consent; 2. healthy male volunteers aged 20-25 years; 3. weight not less than 50Kg, and body mass index(BMI)within the range of 19-25 kg/m2,the weight deviation was not more than 10%; 4. No history of heart, liver, kidney, gastrointestinal tract, nervous system, mental disorders and metabolic disorders, no history of allergies, and no history of severe infections and serious injury; 5. Results or values of physical examinations, ECGs, an clinical laboratory tests are normal or within the acceptable range of sponsor / investigator; 6. No hobby of alcoho and smoking, prohibited from smoking, having food or beverages containing grapefruit juice, tobacco, alcohol, caffeine,and or xanthine 1 week before or during the study.

Exclusion criteria

Exclusion criteria: 1. Known severe allergies or allergic reactions to the test preparation, and/or any of its ingredients or the relative preparations; 2. History of diseases in central nervous system, cardiovascular, respiratory, digestive, genitourinary, endocrine and metabolic, hematopoietic system and spirit of the system; 3. History of disease that may affect the evaluation of preparations; History of surgery or medical conditions that may affect absorption, distribution, metabolism or excretion of preparations; 4. Posotive result of Hepatitis B surface antigen (HBsAg), HCV and HIV antibody; 5. Use of any prescriptions or Chinese herbal medicine 4 weeks before screening; Use of any non-prescription drugs and food supplements (vitamins, etc.) 2 weeks before screening; 6. Participated in any clinical trials 3 months before screening; 7. Blood donation or blood loss >=400mL 3 months before screening; 8. Has spontaneous abnormal eg, recurrent syncope, palpitations, etc.) 1 year before screening and/or current; 9. History of alcohol abuse, more than a big bottle of beer everyday; 10. Do not follow the restrictions on alcohol and tobacco: smoking, drinking caffeinated beverages, or eat food or drink of any alcoholic or xanthine from 48 hours prior to drug administration till the end of the study.

Design outcomes

Primary

MeasureTime frame
bioactive lignans dose–response relationship for WZC’s impact on boosting of TAC and the potential f;

Countries

China

Contacts

Public ContactWansheng Chen
chenwanshengchzh@yahoo.com.cn+86 21 81886999

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026